Tempus AI study shows pre-screening panel exceeds 80% sensitivity across 12 lung cancer biomarkers
TEM•Tempus AI said its pre-screening panel exceeded 80% sensitivity across 12 lung cancer biomarkers in an analysis of 60,459 cases from 56,969 patients conducted with Pfizer.
1. Study results
Tempus AI said its AI-enabled panel analyzes routine pathology images to help identify advanced non-small cell lung cancer patients who may need biomarker testing. Results were presented at the European Society for Medical Oncology Congress 2026 in Madrid. The panel remains in development as a tool to guide subsequent testing, not replace established molecular or immunohistochemistry tests.
